Results 21 to 30 of about 419,957 (200)

GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics.

Nucleic Acid Therapeutics, 2018
Short-interfering RNA (siRNA)-induced RNAi responses have great potential to treat a wide variety of human diseases from cancer to pandemic viral outbreaks to Parkinson's Disease.
Aaron D. Springer, S. Dowdy
semanticscholar   +1 more source

Anti-Metastatic Effects on Melanoma via Intravenous Administration of Anti-NF-κB siRNA Complexed with Functional Peptide-Modified Nano-Micelles

Pharmaceutics, 2020
Controlling metastasis is an important strategy in cancer treatment. Nanotechnology and nucleic acids with novel modalities are promising regulators of cancer metastasis.
Hisako Ibaraki, Takanori Kanazawa, Minami Owada, Keiko Iwaya, Yuuki Takashima, Yasuo Seta   +5 more
doaj   +1 more source

On the Formation and Morphology of Lipid Nanoparticles Containing Ionizable Cationic Lipids and siRNA.

ACS Nano, 2018
Lipid nanoparticles (LNPs) containing short interfering RNA (LNP-siRNA) and optimized ionizable cationic lipids are now clinically validated systems for silencing disease-causing genes in hepatocytes following intravenous administration.
J. Kulkarni, Maria M Darjuan, Joanne E. Mercer, Sam Chen, R. van der Meel, J. Thewalt, Y. Y. Tam, P. Cullis   +7 more
semanticscholar   +1 more source

siRNA nanoparticles targeting CaMKIIγ in lesional macrophages improve atherosclerotic plaque stability in mice

Science Translational Medicine, 2020
Targeted siRNA nanoparticles can specifically inhibit pro-atherogenic macrophage pathways to combat atherosclerotic vascular disease. Perturbing plaque macrophages Macrophages in atherosclerotic lesions promote inflammation and plaque progression and are
Wei Tao, Arif Yurdagul, Na Kong, Wenliang Li, Xiaobo Wang, Amanda C. Doran, Chan Feng, Junqing Wang, M. Islam, O. Farokhzad, I. Tabas, Jinjun Shi   +11 more
semanticscholar   +1 more source

Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.

Accounts of Chemical Research, 2019
Delivering nucleic acid-based therapeutics to cells is an attractive approach to target the genetic cause of various diseases. In contrast to conventional small molecule drugs that target gene products (i.e., proteins), genetic drugs induce therapeutic ...
J. Kulkarni, D. Witzigmann, Sam Chen, P. Cullis, R. van der Meel   +4 more
semanticscholar   +1 more source

Overcoming Barriers for siRNA Therapeutics: From Bench to Bedside

Pharmaceuticals, 2020
The RNA interference (RNAi) pathway possesses immense potential in silencing any gene in human cells. Small interfering RNA (siRNA) can efficiently trigger RNAi silencing of specific genes.
M. Sajid, M. Moazzam, Shun Kato, Kayley Yeseom Cho, R. Tiwari   +4 more
semanticscholar   +1 more source

Autophagy Modulators: Mechanistic Aspects and Drug Delivery Systems

Biomolecules, 2019
Autophagy modulation is considered to be a promising programmed cell death mechanism to prevent and cure a great number of disorders and diseases. The crucial step in designing an effective therapeutic approach is to understand the correct and accurate ...
Shima Tavakol, Milad Ashrafizadeh, Shuo Deng, Maryam Azarian, Asghar Abdoli, Mahsa Motavaf, Delaram Poormoghadam, Hashem Khanbabaei, Elham Ghasemipour Afshar, Ali Mandegary, Abbas Pardakhty, Celestial T. Yap, Reza Mohammadinejad, Alan Prem Kumar   +13 more
doaj   +1 more source

Potentiating tumor immunity using aptamer-targeted RNAi to render CD8+ T cells resistant to TGFβ inhibition

OncoImmunology, 2018
TGFβ secreted by tumor cells and/or tumor infiltrating stromal cells is a key mediator of tumor growth and immune suppression at the tumor site. Nonetheless, clinical trials in cancer patients targeting the TGFβ pathway exhibited at best a modest ...
Yvonne Puplampu-Dove, Tal Gefen, Anugraha Rajagopalan, Darija Muheramagic, Brett Schrand, Eli Gilboa   +5 more
doaj   +1 more source

Lipid and Polymer-Based Nanoparticle siRNA Delivery Systems for Cancer Therapy

Molecules, 2020
RNA interference (RNAi) uses small interfering RNAs (siRNAs) to mediate gene-silencing in cells and represents an emerging strategy for cancer therapy. Successful RNAi-mediated gene silencing requires overcoming multiple physiological barriers to achieve
F. Mainini, M. Eccles
semanticscholar   +1 more source

Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

Nature, 2010
Therapeutics that are designed to engage RNA interference (RNAi) pathways have the potential to provide new, major ways of imparting therapy to patients.
Mark E. Davis, J. Zuckerman, C. H. J. Choi, D. Seligson, A. Tolcher, C. Alabi, Y. Yen, J. Heidel, A. Ribas   +8 more
semanticscholar   +1 more source